| Over a week ago | ||||
Natus Medical announced… Natus Medical announced the acquisition of Babybe GmbH and its patented remote mother to baby communication technology. The Babybe technology will add to Natus's market leading Newborn Care portfolio of products. Babybe offers an innovative new way to remotely connect a mother and her baby in the neonatal intensive care unit. With this technology, mother and baby are connected in real time through heartbeat, breathing and vocal sounds using an active mattress system. Clinical studies are currently underway to assess how the mother and baby connection impacts weight gain, apnea and neuro-development in premature newborns who are isolated in the NICU. Natus expects the Babybe product to be available in commercial quantities in early 2022. | ||||
| Over a quarter ago | ||||
Natus Medical announced a… Natus Medical announced a partnership with Holberg EEG AS. The partnership will advance the development and distribution of an AutoSCORE algorithm to automate Electroencephalography classifications and improve reporting efficiency. Holberg EEG has developed and commercialized SCORE EEG, a reporting and database software that builds on the new international consensus for describing EEG examinations and replaces free text reporting. The new partnership will advance the next steps to develop AutoSCORE, which will provide decision support to reduce EEG reporting variability, improve quality, and reduce time and cost for users. AutoSCORE has the potential to improve clinical outcome and value of care for the millions suffering from epilepsy. | ||||
Natus Medical (NTUS)… Natus Medical (NTUS) announced the appointment of Ilan Daskal, current CFO & EVP of Bio-RAD Laboratories (BIO), to its board of directors and audit committee effective March 19, 2020. The Company will also nominate Daskal at its 2020 Annual Meeting of Stockholders. Kenneth Ludlum has advised the board that he will not stand for re-election at the 2020 Annual Meeting of Stockholders. Following Mr. Ludlum's retirement, the Natus board will be composed of seven directors. | ||||
The adjustments resulted… The adjustments resulted in a GAAP net income of $3.0M for Q4, compared to $3.2M previously reported, or 9c per diluted share, compared to 10c previously reported, and a non-GAAP net income of $15.6M, compared to $15.4M previously reported, or 46c per diluted share, which remained the same as previously reported. | ||||
The adjustments resulted… The adjustments resulted in a GAAP net income of $3.0M for Q4, compared to $3.2M previously reported, or 9c per diluted share, compared to 10c previously reported, and a non-GAAP net income of $15.6M, compared to $15.4M previously reported, or 46c per diluted share, which remained the same as previously reported. | ||||
Sees Q1 revenue… Sees Q1 revenue $113M-$117M, consensus $116M. | |
Reports Q4 revenue… Reports Q4 revenue $131.8M, consensus $130M. "Our Neuro business showed significant growth during the quarter with a 14.5% increase in year over year after adjusting for the divestiture of GND, driven by new cybersecurity features and Windows(R) 10 upgrades in our EEG products as well as strength in our sleep and neurosurgery business. Overall, we achieved organic revenue growth of 1% after adjusting for our divestitures. Our non-GAAP gross profit margins improved 390 basis points during the quarter. Strong operating cash flows of $12.7 million and another $15 million in debt reduction put Natus in a net cash position at the end of the year," said Jonathan Kennedy, President and Chief Executive Officer of Natus. "Both the Newborn Care and the Hearing & Balance businesses declined during the quarter. However, we expect them to return to growth in the first quarter of 2020 as we return key products to the market." | |
IRADIMED CORPORATION… IRADIMED CORPORATION (IRMD) announced the retirement of Brent Johnson, EVP of Worldwide Sales and Marketing, effective April 10, 2020 after leading the company's commercial efforts since 2012. IRADIMED appointed MaryBeth Smith as VP of Worldwide Sales, succeeding Johnson, effective January 20, 2020. Smith will report to Leslie McDonnell, President and CEO. Prior to her appointment at IRADIMED, Smith spent more than 20 years at Natus Medical (NTUS), most recently as the VP of Sales and Sales Operations for newborn care products. | |
Natus Medical… Natus Medical Incorporated (NTUS) announced that effective December 31, 2019 the company has finalized and executed the previously announced transition of the Peloton hearing screening services business to Pediatrix Medical Group. Pediatrix Medical Group, a MEDNAX, Inc. (MD) company, will manage all newborn hearing screening services for Peloton hospitals while Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business. Installation of ALGO screeners at the Pediatrix hospitals is expected to be completed during 2020. |